Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients

Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference

AACR Special Conference on Tumor Immunology and Immunotherapy

Nov 19, 2019 • 4:30pm EST

SITC 34th Annual Meeting

Nov 8, 2019 • 7:00am EST